Abstract：
UNASSIGNED: Medications for opioid use disorder (MOUD) include opioid agonist therapies (OAT) (buprenorphine and methadone), and opioid antagonists (extended-release naltrexone). All forms of MOUD improve opioid use disorder (OUD) and HIV outcomes. However, the integration of services for HIV and OUD remains inadequate. Persistent barriers to accessing MOUD underscore the immediate necessity of addressing pharmacoequity in the treatment of OUD in persons with HIV (PWH).
UNASSIGNED: In this review article, we specifically focus on OAT among PWH as it is the most commonly utilized form of MOUD. Specifically, we delineate the intersection of HIV and OUD services, emphasizing their integration into the United States Ending the HIV Epidemic (EHE) plan by offering comprehensive screening, testing, and treatment for both HIV and OUD. We identify potential drug interactions of OAT with antiretroviral therapy (ART), address disparities in OAT access, and present the practical benefits of long-acting formulations of buprenorphine, ART, and pre-exposure prophylaxis for improving HIV prevention and treatment, and OUD management.
UNASSIGNED: Optimizing OUD outcomes in PWH necessitates careful attention to diagnosing OUD, initiating OUD treatment, and ensuring medication retention. Innovative approaches to healthcare delivery, such as mobile pharmacies, can integrate both OUD and HIV and reach underserved populations.
UNASSIGNED: In this review article, we specifically focus on OAT among PWH as it is the most commonly utilized form of MOUD. Specifically, we delineate the intersection of HIV and OUD services, emphasizing their integration into the United States Ending the HIV Epidemic (EHE) plan by offering comprehensive screening, testing, and treatment for both HIV and OUD. We identify potential drug interactions of OAT with antiretroviral therapy (ART), address disparities in OAT access, and present the practical benefits of long-acting formulations of buprenorphine, ART, and pre-exposure prophylaxis for improving HIV prevention and treatment, and OUD management.
UNASSIGNED: Optimizing OUD outcomes in PWH necessitates careful attention to diagnosing OUD, initiating OUD treatment, and ensuring medication retention. Innovative approaches to healthcare delivery, such as mobile pharmacies, can integrate both OUD and HIV and reach underserved populations.
摘要：
■阿片类药物使用障碍（MOUD）包括阿片类药物激动剂疗法（OAT）（丁丙诺啡和美沙酮），和阿片类拮抗剂（缓释纳曲酮）。所有形式的MOUD都可以改善阿片类药物使用障碍（OUD）和HIV结局。然而,艾滋病毒和OUD服务的整合仍然不足。获得MOUD的持续障碍强调了在艾滋病毒感染者（PWH）的OUD治疗中解决药物公平性的迫切需要。
■在这篇评论文章中，我们特别关注PWH中的OAT，因为它是最常用的MOUD形式。具体来说,我们描绘了HIV和OUD服务的交叉点，通过提供全面的筛查，强调他们融入美国结束艾滋病毒流行（EHE）计划，测试,以及对HIV和OUD的治疗。我们确定了OAT与抗逆转录病毒疗法（ART）的潜在药物相互作用，解决OAT访问中的差异，并展示了丁丙诺啡长效制剂的实际好处，ART,和暴露前预防，以改善艾滋病毒的预防和治疗，和OUD管理。
■优化PWH中的OUD结果需要仔细注意诊断OUD，开始OUD治疗，并确保药物保留。提供医疗保健的创新方法，例如移动药房，可以整合OUD和艾滋病毒，并覆盖服务不足的人群。
■在这篇评论文章中，我们特别关注PWH中的OAT，因为它是最常用的MOUD形式。具体来说,我们描绘了HIV和OUD服务的交叉点，通过提供全面的筛查，强调他们融入美国结束艾滋病毒流行（EHE）计划，测试,以及对HIV和OUD的治疗。我们确定了OAT与抗逆转录病毒疗法（ART）的潜在药物相互作用，解决OAT访问中的差异，并展示了丁丙诺啡长效制剂的实际好处，ART,和暴露前预防，以改善艾滋病毒的预防和治疗，和OUD管理。
■优化PWH中的OUD结果需要仔细注意诊断OUD，开始OUD治疗，并确保药物保留。提供医疗保健的创新方法，例如移动药房，可以整合OUD和艾滋病毒，并覆盖服务不足的人群。
